Company news

CytoSorbents Corporation news in 2023

CytoSorbents Corporation's news releases, calls and decks from 2023, newest first.

View company

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

December 27, 2023

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

December 12, 2023

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

November 8, 2023

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

October 26, 2023

CytoSorbents to Present at the 8th Annual Dawson James Conference

October 4, 2023

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

September 26, 2023

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

September 18, 2023

CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation

September 10, 2023

CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico

August 31, 2023

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

August 30, 2023

CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial

August 13, 2023

CytoSorbents Reports Second Quarter 2023 Financial and Operational Results

July 31, 2023

CytoSorbents to Report Second Quarter 2023 Operating and Financial Results

July 25, 2023

CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer

July 18, 2023

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease

July 10, 2023

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

July 6, 2023

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

June 14, 2023

CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference

June 4, 2023

CytoSorbents Reports First Quarter 2023 Results

May 1, 2023

CytoSorbents to Report First Quarter 2023 Operating and Financial Results

April 25, 2023

CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled

April 19, 2023

CytoSorbents Announces Board Chairman Al W. Kraus To Retire

April 18, 2023

Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation

March 28, 2023

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

March 21, 2023

CytoSorbents Comments on Bank Exposure and Diversified Cash Position

March 13, 2023

CytoSorbents Reports Fourth Quarter and Full Year 2022 Results

March 8, 2023

CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference

February 26, 2023

CytoSorbents to Report Fiscal 2022 Operating and Financial Results

February 23, 2023

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

January 30, 2023

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

January 22, 2023

CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

January 16, 2023

Calls in 2023

Decks in 2023